Benzinga's Top #PreMarket Losers
April 28, 2014 at 08:09 AM EDT
Athersys (NASDAQ: ATHX) dropped 52.38% to $1.30 in pre-market trading on failed trial results for ulcerative colitis. OncoGenex ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.